Analyst favorites — what the screen found 2026-11-09
Manufacturing dominates the latest results, accounting for 27 of the 40 companies that matched the screen on November 6, 2026. This concentration suggests a cluster in one area rather than a broad market spread.
Key figures
Data as of Nov 9, 2026- AVBP (ArriVent BioPharma, Inc. Common Stock) market cap
- $679.95M
- MMYT (MakeMyTrip Limited) market cap
- $4.81B
- CSTL (Castle Biosciences, Inc. Common Stock) market cap
- $1.00B
- FWRG (First Watch Restaurant Group, Inc. Common Stock) market cap
- $798.74M
- PVLA (Palvella Therapeutics, Inc. Common Stock) market cap
- $2.51B
- OVID (Ovid Therapeutics Inc. Common Stock) market cap
- $561.48M
Manufacturing dominates the latest results, accounting for 27 of the 40 companies¹˒² that matched the screen on November 6, 2026. This concentration suggests a cluster in one area rather than a broad market spread.
The results include names across various sectors and sizes, such as ArriVent BioPharma ($679.95M)³, Palvella Therapeutics ($2.51B)⁴, and Ovid Therapeutics ($561.48M)⁵, all within Manufacturing. Other matches include MakeMyTrip Limited ($4.81B)⁶, Castle Biosciences ($1.00B) in Services⁷, and First Watch Restaurant Group ($798.74M) in Retail Trade⁸.
Every company on this list shares a strong-buy-leaning consensus from analysts⁹. The analyst ratings across all 40 matches range from 1.0 to 1.19¹⁰, with a median rating of 1.14¹¹.
Passing this test establishes that a crowd of analysts currently views these stocks favorably, but it does not establish that any of these companies are worth owning. This is a starting list based on documented bullish leanings, not a final verdict on value or future performance. The screen filters for specific data points on a single date and does not determine what happens next.